Sun Pharma Share Price (SUNPHARMA)
as on
| Source : NSE
Sun Pharma Stock Performance
as on August 18, 2025 at 2:55 PM IST
Day's Low
Day's High
₹1,625.4₹1,649.6
0.59%
Downside
0.89%
Upside
52 Week's Low
52 Week's High
₹1,553.05₹1,960.355.02%
Downside
19.89%
Upside
| Market Stats | |
| Previous Close | ₹1,641.40 |
| Open | ₹1,635.10 |
| Volume | 22.75L |
| Upper Circuit | ₹1,805.50 |
| Lower Circuit | ₹1,477.30 |
| Day's Low | ₹1,625.4 |
| Day's High | ₹1,649.6 |
| 52 Week Low | ₹1,553.05 |
| 52 Week High | ₹1,960.35 |
| Returns % | |
| 1 Month Return | -3.08 % |
| 3 Month Return | -5.13 % |
| 1 Year Return | -6.09 % |
| 3 Year Return | + 79.05 % |
| 5 Year Return | + 212.05 % |
Sun Pharma Stock Fundamentals & Key Indicators
Check Sun Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹3,93,826.84 Cr
Return on Equity (ROE)
17.83
PE Ratio (TTM)
37.91
Return on capital employed (ROCE)
16.29
Beta (LTM)
0.62
P/B Ratio
17.11
Dividend Yield
0.92
PEG Ratio
0Quarterly Earnings Growth YOY
-19.8
EPS (TTM)
45.76
Sector
Pharmaceuticals
Book Value
301
Technical Analysis
Bearish
View Technical Analysis
Sun Pharma Stock's Interest Amongst Investors
Sun Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Sun Pharma.
based on 38 analysts
81.58%
Buy
10.53%
Hold
7.89%
Sell
81.58% of analysts recommend a 'BUY' rating for Sun Pharma. Average target price of ₹1934.37
Source: S&P Global Market Intelligence
Sun Pharma Share Price Target
Get share price movements and forecasts by analysts on Sun Pharma.
Sun Pharma price forecast by 38 analysts
Upside of17.85%
High
₹2450
Target
₹1934.37
Low
₹1525
Sun Pharma target price ₹1934.37, a slight upside of 17.85% compared to current price of ₹1635.1. According to 38 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:20.11%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:24.61%
Forecast
Actual
Source: S&P Global Market Intelligence
Sun Pharmaceutical Industries Ltd Financial Results
Get the annual and quarterly financial summary of Sun Pharmaceutical Industries Ltd, including revenue, profit, loss and more.
Sun Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Sun Pharma.
Sun Pharmaceutical Industries Ltd Earnings Results
Sun Pharmaceutical Industries Ltd’s net profit fell -19.64% since last year same period to ₹2,278.63Cr in the Q1 2025-2026. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated 5.99% jump in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceutical Industries Ltd Dividends May,2025
In the quarter ending March 2025, Sun Pharmaceutical Industries Ltd has declared dividend of ₹5.50 per share on 22 May 2025 - translating a dividend yield of 1.28%.
Read More about Dividends
Indices Featuring Sun Pharma Stock
Check stock indices that include Sun Pharma.
Sun Pharma Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Sun Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 17.26% | ||
| Mutual Funds | 12.63% | 3.43 | |
| Retail Investors | 8.77% | ||
| Others | 6.86% | 5.84 |
Sun Pharmaceutical Industries Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Sun Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 3,93,826.84 | 42.41% | 0.52 | 10,980 | 52,578 | |
| HOLD | 1,62,798.61 | 18.93% | 0.50 | 2,191 | 9,360 | |
| BUY | 1,22,613.28 | 31.66% | 0.66 | 1,911 | 11,516 | |
| BUY | 48,030.42 | -1.8% | 0.78 | 1,429 | 15,261 | |
| HOLD | 32,552.57 | 1.72% | 0.53 | 698 | 5,616 |
Sun Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Sun Pharma.
Sun Pharma Faces Sales Decline Amid Analyst Meetings - 12 Aug, 2025
Sun Pharmaceutical Industries Ltd faces challenges with a 42.65% decline in June 2025 net sales. Analysts are monitoring the stock, while investor meetings are scheduled in Mumbai.Sun Pharma Faces Pressure Amid Tariff Hike Warnings - 06 Aug, 2025
Sun Pharmaceutical Industries Ltd experienced significant selling pressure as the Nifty Pharma index dropped over 2% following US President Trump's tariff hike warnings on imported medicines.Sun Pharma Reports Mixed Q1 Results Amid Strength - 31 Jul, 2025
Sun Pharmaceutical Industries Ltd reported a 20% decline in net profit for Q1FY26 due to exceptional charges, despite a 9.4% rise in revenue. The stock shows renewed strength, breaking out of a consolidation phase, indicating a bullish outlook.Sun Pharma Q1 Preview Shows Steady Growth Prospects - 30 Jul, 2025
Sun Pharmaceutical Industries is set to announce Q1FY26 results, with analysts projecting growth in India and US specialty sales, despite anticipated margin pressures from new launches and forex losses.Sun Pharma Settles Antitrust Claims, Advances Clinical Study - 25 Jul, 2025
Sun Pharmaceutical Industries has settled U.S. antitrust claims for $200 million related to generic drug pricing. Additionally, they announced an ongoing clinical study for tildrakizumab, a treatment for genital psoriasis, which could influence market dynamics.Sun Pharma Settles US Antitrust Case for $200 Million - 24 Jul, 2025
Sun Pharmaceutical Industries announced a $200 million settlement for US antitrust litigation involving its subsidiaries. The settlement is subject to court approval and does not imply wrongdoing.Sun Pharma's ILUMYA Shows Positive PsA Trial Results - 21 Jul, 2025
Sun Pharmaceutical Industries announced positive results from two Phase 3 trials for ILUMYA, demonstrating significant improvements in psoriatic arthritis symptoms. Both trials met primary endpoints, reinforcing ILUMYA's therapeutic potential. The drug is currently approved for plaque psoriasis but remains investigational for psoriatic arthritis.Sun Pharma Launches Leqselvi After Patent Settlement - 14 Jul, 2025
Sun Pharmaceutical Industries has launched Leqselvi in the U.S. after settling a patent dispute with Incyte. Morgan Stanley gives it an Overweight rating, predicting significant sales potential for the drug, which addresses severe alopecia areata. The launch marks a key milestone in Sun's dermatology portfolio.
Insights on Sun Pharmaceutical Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 7 days, SUNPHARMA stock has moved up by 2.1%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 2.14K Cr → 2.27K Cr (in ₹), with an average increase of 5.7% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 13.57K Cr → 14.31K Cr (in ₹), with an average increase of 5.2% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 12.21% to 12.63% in Jun 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 31.3% return, outperforming this stock by 37.4%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 132.1% return, outperforming this stock by 53.0%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Jun 2025 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 17.96% to 17.26% in Jun 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 8.87% to 8.77% in Jun 2025 quarter
About Sun Pharmaceutical Industries Ltd
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Revenue: ₹13,786.07Cr as on June 2025 (Q1 FY26)
Net Profit: ₹2,302.62Cr as on June 2025 (Q1 FY26)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharmaceutical Industries Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Mutual Funds that own Sun Pharma Stock
Check out the Mutual Funds with significant holdings in Sun Pharma.
FAQs
What is Sun Pharma share price today?
Sun Pharma share price today stands at ₹1635.1, Open: ₹1635.1, Previous Close: ₹1641.4, High: ₹1649.6, Low: ₹1625.4, 52 Week High: ₹1960.35, 52 Week Low: ₹1553.05 as on .
How to buy Sun Pharma shares ?
To buy Sun Pharma shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for SUNPHARMA or Sun Pharmaceutical Industries Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Sun Pharma shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Sun Pharma?
Today's traded volume of Sun Pharma is 22.75L. Which means that 22.75L shares of Sun Pharma were bought and sold on the stock market during today's trading session.
What is Sun Pharma's market cap today?
Today's market capitalisation of Sun Pharma is ₹3,93,826.84 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Sun Pharma?
Sun Pharma’s 52 week high is ₹1960.35 and 52 week low is ₹1553.05. The current share price of Sun Pharma is ₹1635.1, which is -16.59% down from its 52 week high and 5.28% up from its 52 week low.